Adrenoleukodystrophy Market

Adrenoleukodystrophy Market - Global Industry, Analysis, Size, Share, Growth, Trends, and Forecasts 2023-2030

Adrenoleukodystrophy (ALD) is a genetic condition in which group of neurological conditions known as leukodystrophies. Leukodystrophies are disorders that result from abnormalities in myelin, the white matter-like damage in the membrane (myelin sheath) that covers nerve cells in the brain and spinal cord. Myelin acts as insulation around the nerve fibers. When this isolating neve damaged, nerve signals from the brain cannot communicate across the body properly, causing impaired bodily functions or paralysis. Adrenoleukodystrophy also known as X-linked adrenoleukodystrophy or X-ALD, is a genetic disease that results from a mutated gene on the X chromosomes.  Adrenoleukodystrophy prevents the body from breaking down very long chain fatty acids, causing these fatty acid chains to build up in the brain, nervous system, and adrenal glands. The accumulation is thought to cause inflammation in the body, damaging the myelin sheath. Symptoms of adrenoleukodystrophy like loss of vision, learning disabilities, dysphagia, lack of coordination and balance, progressive dementia, and muscle weakness often begin between the ages of 4 to 10 but can also present much later in life.

Regular monitoring to detect the onset of adrenal failure and conversion to cerebral adrenoleukodystrophy is recommended in all male patients. Hematopoietic cell transplant (HCT) is the treatment of choice for cerebral ALD. The guideline addresses a clinical need in the adrenoleukodystrophy community worldwide as the number of overall diagnoses and presymptomatic individuals is increasing because of newborn screening and the greater availability of next-generation sequencing. The poor ability to predict the disease course informs current monitoring intervals but remains subject to change as more data emerge. This knowledge gap should direct future research and illustrate once again that international collaboration among physicians, researchers, and patients is essential to improving care.

Global Adrenoleukodystrophy Market – Competitive Landscape

In January 2023, Ipsen and Albireo entered into a definitive merger agreement under which Ipsen will acquire Albireo. The anticipated acquisition will enrich Ipsen’s rare disease portfolio and pipeline. In 2022, Minoryx raised USD 51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support marketing authorization and launched preparation for X-linked adrenoleukodystrophy therapy.

Some of the Key Players in the Global Adrenoleukodystrophy Market Include

  • Bluebird Bio Inc
  • Ashvattha Therapeutics LLC.
  • MedDay SA
  • Minoryx Therapeutics
  • Nutra Pharma Corp
  • Poxel SA
  • Magenta Therapeutics Inc
  • SOM Biotech SL
  • Viking Therapeutics Inc.

Global Adrenoleukodystrophy Market – Growth Drivers

The global prevalence rate of adrenoleukodystrophy, according to the U.S. National Library of Medicine, is 1 in 20,000 to 50,000 individuals worldwide. This increased prevalence, in turn, raises awareness and motivates governments to focus on providing financial support for research and development (R&D). Ongoing research in the field of adrenoleukodystrophy leads to a better understanding of the disease, its diagnosis, and the development of more targeted therapies. Governments and regulatory bodies often grant orphan drug designation to treatments for rare diseases like adrenoleukodystrophy. Collaborations between pharmaceutical companies, organizations, and research institutions can accelerate market expansion. The successful completion of clinical trials and regulatory approvals for new adrenoleukodystrophy treatments can significantly impact market growth..

Global Adrenoleukodystrophy Market – Restraints

The increasing cost burden on the national healthcare system, including adrenoleukodystrophy in screening programs, according to the adrenoleukodystrophy newsletter, will add extra costs of about USD 520,000 to the overall expenditure. However, early detection of X-ALD through screening will result in an overall cost savings of USD 3.9 million per year, which includes lifetime healthcare, social care, and education expenses.

Adrenoleukodystrophy is a rare disorder, which means there is a limited patient population. This small market size can make it less attractive for pharmaceutical companies to invest in research and development. Gaining regulatory approvals for treatments of rare diseases can be a lengthy and challenging process. Economic downturns or financial constraints in the healthcare system can impact funding for research and access to care.

Global Adrenoleukodystrophy Market – Opportunities

Advances in gene therapy, enzyme replacement therapy, and other treatment approaches offer opportunities for the development of innovative therapies. Adrenoleukodystrophy treatments can benefit from orphan drug status, which provides financial incentives, exclusive market access, and increased attractiveness for pharmaceutical companies. The growing awareness of rare diseases worldwide creates opportunities for market expansion in various regions. Advanced technologies, such as artificial intelligence and data analytics, can aid in researching, diagnosing, and monitoring Adrenoleukodystrophy patients.

Global Adrenoleukodystrophy Market – Geographical Insight

The market for global adrenoleukodystrophy is segmented into the regions of North America, Latin America, Asia-Pacific, Europe, the Middle East & Africa. North America is the largest adrenoleukodystrophy market in which the countries like United States and Canada have advanced healthcare systems with high awareness of rare diseases. In Europe, particularly in Western Europe countries like the UK, Germany, and France have well-established healthcare systems and research capabilities and in Eastern Europe countries have low awareness and limited access to healthcare treatments. In Asia-Pacific countries like China, with its vast population showing increasing diagnosis rates, and represents a growing market for adrenoleukodystrophy treatments.

Global Adrenoleukodystrophy Market – Key Development

  • On September 14, 2022, Minoryx Therapeutics a later-stage biotech company focused on the development of treatments for orphan central nervous system disorders, filed a Marketing Authorization Application (MAA) for its lead candidate Leriglitazone for the treatment of adult male patients with X-linked adrenoleukodystrophy.
  • On 17 May 2022, Poxel announced that PXL065 and PXL770 were granted orphan drug designation from the U.S. FDA for X-linked adrenoleukodystrophy.
Complete the form below and we'll get back to you shortly
Table of Content
Complete the form below and we'll get back to you shortly
cognizance market research(cmr)

Adrenoleukodystrophy Market


Black Friday Offers (40% Off)​

Don’t Miss Out On The Biggest Savings Of The Year!

- Get Started -

Get insights that lead to new growth opportunities

Need a Custom Report?

We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Business Development

small c popup.png

Black Friday Offers (40% Off)

Don't miss out on the biggest savings of the year!

small c popup.png
Buy Now
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
small c popup.png
Complete the form below and we'll get back to you shortly
Ask an Expert